2017/18 Invitation to Tender – additional pharmaceuticals

PHARMAC welcomes all feedback on this proposal to include additional pharmaceuticals in the 2017/18 Tender. Feedback received by the deadline may be considered by the Tender Medical Evaluation Subcommittee of PTAC and would be considered by the PHARMAC Board (or its Delegate, where applicable) prior to making a decision on this proposal. 

Feedback should be submitted by the following dates; late feedback may not be considered:

Feedback should be provided by submitting an email or letter to the Tender Analysts:

Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA. Anyone providing feedback, whether on their own account or on behalf of an organisation, and whether in a personal or professional capacity, should be aware that the content of their feedback and their identity may need to be disclosed in response to an OIA request.     

We are not able to treat any part of your feedback as confidential unless you specifically request that we do, and then only to the extent permissible under the OIA and other relevant laws and requirements. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like it withheld.  PHARMAC will give due consideration to any such request.

Details

On 3 August 2017 PHARMAC released the draft 2017/18 Invitation to Tender, seeking feedback on a proposed list of pharmaceuticals for sole supply, the draft process and terms and conditions for the 2017/18 Invitation to Tender and commercial proposals as an alternative to tendering.

PHARMAC now wishes to seek feedback on additional pharmaceuticals that were not included in the original proposal to tender certain pharmaceuticals for sole supply but which we now are proposing to include in the 2017/18 Invitation to Tender.

We are seeking comments, in particular as to whether any of the additional pharmaceuticals, you consider would be inappropriate to tender, and the reasons for that view, including any contractual constraints or patent protection that could restrict PHARMAC from awarding a tender on a particular pharmaceutical.   

Please note that feedback is only sought on the additional pharmaceuticals listed below and not on the draft process and terms and conditions for the 2017/18 Invitation to Tender.

Please also note that PHARMAC will not accept any Alternative Commercial Proposals for these additional pharmaceuticals.

Additional pharmaceuticals listed below: